



HAL
open science

The Importance Of Naturally Attenuated Sars-Cov-2 In The Fight Against Covid-19

J. Armengaud, Agnès Delaunay-Moisan, Jean-Yves Thuret, Eelco Van Anken, Diego Acosta-Alvear, Tomás Aragón, Carolina Arias, Marc Blondel, Ineke Braakman, Jean-François Collet, et al.

► **To cite this version:**

J. Armengaud, Agnès Delaunay-Moisan, Jean-Yves Thuret, Eelco Van Anken, Diego Acosta-Alvear, et al.. The Importance Of Naturally Attenuated Sars-Cov-2 In The Fight Against Covid-19. *Environmental Microbiology*, 2020, 22 (6), pp.1997-2000. <10.1111/1462-2920.15039>. <hal-02571406>

HAL Id: hal-02571406

<https://hal.science/hal-02571406v1>

Submitted on 8 Dec 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC-ND 4.0 - Attribution - Non-commercial use - No Derivative Works - International License

Opinion

The importance of naturally attenuated SARS-CoV-2 in the fight against COVID-19

Jean Armengaud ^{1*}, Agnès Delaunay-Moisan,^{2*}
Jean-Yves Thuret ^{2*}, Eelco van Anken ^{3*},
Diego Acosta-Alvear ⁴, Tomás Aragón ⁵,
Carolina Arias ⁴, Marc Blondel ^{6,7,8,9},
Ineke Braakman ¹⁰, Jean-François Collet ^{11,12},
René Courcol ¹³, Antoine Danchin ¹⁴,
Jean-François Deleuze ¹⁵, Jean-Philippe Lavigne ^{16,17},
Sophie Lucas ^{11,12}, Thomas Michiels ¹¹,
Edward R. B. Moore ^{18,19}, Jonathon Nixon-Abell ²⁰,
Ramon Rossello-Mora ²¹, Zheng-Li Shi ²²,
Antonio G. Siccardi ³, Roberto Sitia ³,
Daniel Tillett ²³, Kenneth N. Timmis ²⁴,
Michel B. Toledano ², Peter van der Sluijs ¹⁰ and
Elisa Vicenzi ²⁵

¹Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SPI, Bagnols-sur-Cèze, 30200, France.

²Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, 91198, France.

³Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Università Vita-Salute San Raffaele, Via Olgettina 58, Milan, 20132, Italy.

⁴Department of Molecular, Cellular, and Developmental Biology, University of California, Santa Barbara, Santa Barbara, CA, 93106.

⁵Center for Applied Medical Research, Department of Gene Therapy and Regulation of Gene Expression, University of Navarra, 55 Pio XII Street, Pamplona, 31008, Spain.

⁶Institut National de la Santé et de la Recherche Médicale UMR1078, 22 Avenue Camille Desmoulins, Brest, F-29200, France.

⁷Université de Bretagne Occidentale, Faculté de Médecine et des Sciences de la Santé, 22 Avenue Camille Desmoulins, Brest, F-29200, France.

Received 22 April, 2020; revised 00 Month, XXXX; accepted 22 April, 2020. *For correspondence. E-mail jean.armengaud@cea.fr; Tel. +33 466796277. E-mail agnes.delaunay-moisan@cea.fr; Tel. +33 169088269. E-mail jean-yves.thuret@cea.fr; Tel. +33 169088193. E-mail evananken@mac.com; Tel. +39 3276321689 †These four co-authors contributed equally and should be considered as first co-authors.

⁸Etablissement Français du Sang (EFS) Bretagne, Brest, F-29200, France.

⁹CHRU Brest, Hôpital Morvan, Laboratoire de Génétique Moléculaire, 22 Avenue Camille Desmoulins, Brest, F-29200, France.

¹⁰Cellular Protein Chemistry, Bijvoet Centre for Biomolecular Science, Science for Life, Utrecht University, The Netherlands.

¹¹de Duve Institute, Université Catholique de Louvain, Brussels, Belgium.

¹²WELBIO, Wallonia, Belgium.

¹³Expertise France, 73 Avenue de Vaugirard, Paris, 75006, France.

¹⁴Stellate Therapeutics/Kodikos, Institut Cochin, Paris, 75014, France.

¹⁵Centre National de Recherche en Génétique Humaine (CNRGH), Institut de Biologie François Jacob, CEA, Université Paris-Saclay, Evry, 91057, France.

¹⁶U1047, Institut National de la Santé et de la Recherche Médicale, Université Montpellier, Montpellier, France.

¹⁷Service de Microbiologie et Hygiène Hospitalière, CHU Nîmes, Nîmes, France.

¹⁸Department of Infectious Diseases, Institute for Biomedicine, Sahlgrenska Academy of the University of Gothenburg, Gothenburg, SE-41346, Sweden.

¹⁹Department of Clinical Microbiology, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, SE-41346, Sweden.

²⁰Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, CB2 0XY, UK.

²¹Marine Microbiology Group, Department of Animal and Bacterial Diversity, IMEDEA (CSIC-UIB), Esporles, Balearic Islands, 07190, Spain.

²²CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People's Republic of China.

²³Nucleics Pty Ltd, 29 John Street, Woollahra, New South Wales, 2025, Australia.

²⁴*Institute of Microbiology, Technical University Braunschweig, Braunschweig, Germany.*

²⁵*Viral Pathogenesis and Biosafety Unit, San Raffaele Scientific Institute, Via Olgettina 58, Milan, 20132, Italy.*

The current SARS-CoV-2 pandemic is wreaking havoc throughout the world and has rapidly become a global health emergency. A central question concerning COVID-19 is why some individuals become sick and others not. Many have pointed already at variation in risk factors between individuals. However, the variable outcome of SARS-CoV-2 infections may, at least in part, be due also to differences between the viral subspecies with which individuals are infected. A more pertinent question is how we are to overcome the current pandemic. A vaccine against SARS-CoV-2 would offer significant relief, although vaccine developers have warned that design, testing and production of vaccines may take a year if not longer. Vaccines are based on a handful of different designs (i), but the earliest vaccines were based on the live, attenuated virus. As has been the case for other viruses during earlier pandemics, SARS-CoV-2 will mutate and may naturally attenuate over time (ii). What makes the current pandemic unique is that, thanks to state-of-the-art nucleic acid sequencing technologies, we can follow in detail how SARS-CoV-2 evolves while it spreads. We argue that knowledge of naturally emerging attenuated SARS-CoV-2 variants across the globe should be of key interest in our fight against the pandemic.

As expected for any RNA virus (Holmes, 2009; Grubaugh *et al.*, 2020), over time, individuals are infected with SARS-CoV-2 variants that typically display some degree of genetic drift, compared with the first isolates of the virus obtained in Wuhan (Genomic epidemiology of hCoV-19 available at <https://www.gisaid.org/epiflu-applications/next-hcov-19-app/>). Indeed, this genetic drift permits SARS-CoV-2 variants to be tracked as they spread around the globe (Forster *et al.*, 2020). We know from studying viral evolution that genetic drift, in particular derived from genomic deletions, will almost inevitably attenuate the pathogenicity of viruses given enough time (Holmes, 2009). It is entirely plausible that, at present, some individuals, by chance, have already become infected with attenuated versions of SARS-CoV-2. Since self-seclusion of the symptomatic and those at high risk has been prompted by many authorities, there may have been, concomitantly, selective advantages for potential attenuated variants of SARS-CoV-2 to spread over non-attenuated variants. Fortunately, COVID-19-related hospitalizations and fatalities have decreased several weeks after lock-down measures were installed in various countries. Clearly, the reduction in

transmission of the non-attenuated virus has been key in these successes. It cannot be excluded, however, that the competition of attenuated strains with the non-attenuated SARS-CoV-2 has also played a role in curbing demand on the health care systems.

Reasoning along these lines, competition of attenuated variants with the non-attenuated SARS-CoV-2 may explain certain particularities in the course of the epidemic at different locations around the globe. Although currently available data on mortality for the SARS-CoV-2-caused pandemic [Novel Coronavirus (COVID-19) Infection Map available at <https://hgis.uw.edu/virus/>] should be interpreted with caution, it seems that case fatality rates tail off even in locations with less effective containment measures. Furthermore, the effects of founder events may shed light on the atypical dynamics of some local epidemics, which pair high numbers of infections with low mortality rates. For example, if many of the first local spreaders of the virus were infected with attenuated strains, the spread of the non-attenuated virus may have been blunted from the onset, due to competition. Mathematical modelling may provide support for these hypotheses in further detail, in particular after more reliable data becomes accessible.

Currently available sequences for SARS-CoV-2 isolates from across the globe confirm that genetic drift is occurring (Grubaugh *et al.*, 2020; Genomic epidemiology of hCoV-19 available at <https://www.gisaid.org/epiflu-applications/next-hcov-19-app/>), although the association between these genetic alterations and severity of clinical outcome are sparse. The only hint at attenuation comes from an observation in Singapore, where some SARS-CoV-2 isolates turned out to have a 382-nucleotide deletion in ORF8 of the viral genome (Su *et al.*, in press). This finding is of particular interest, because a deletion of 29 nucleotides appeared in ORF8 during early spreading of SARS-CoV-1 in 2003. This 29 nucleotide deletion was demonstrated to attenuate viral replication when introduced in an infectious clone generated by reverse genetics (Muth *et al.*, 2018). Likewise, the SARS-Unique Domain in the Nsp3 protein of SARS-CoV-1, which is partially conserved in SARS-CoV-2, has been linked to evasion of host immune recognition, suggesting that the loss of this domain could result in reduced virulence (Snijder *et al.*, 2003; Ma-Laueret *et al.*, 2016; Srinivasan *et al.*, 2020). Based on these examples and others (Benvenuto *et al.*, n.d.), one would expect that attenuated variants of SARS-CoV-2 would emerge as the pandemic unfolds.

We argue that sequencing efforts, thus far, likely underestimate the emergence of attenuated SARS-CoV-2 variants. Most of the isolates that have been analysed are derived from individuals that sought medical care, and, hence, are unlikely to have acquired any features leading to reduced virulence. Instead, currently

existing attenuated SARS-CoV-2 variants should be searched for in the large pool of infected individuals that remain asymptomatic. An interesting aside from an evolutionary perspective is that lock-down and other countermeasures may have accelerated local enrichments of particular SARS-CoV-2 variants. In any case, should particular viral variants be linked to various levels of virus attenuation (or aggressiveness), such findings would have implications for diagnostics, prognostics, disease support management, and eventually, what type of pandemic management policies would be required.

With present-day sequencing prowess, it is feasible to sequence hundreds of thousands of viral genomes, starting from the raw material collected for diagnostic Q-PCR testing. For this, worldwide sequencing platforms could dedicate time and workhorse instruments for sequencing virus-positive samples. We argue that given testing capacity is expanding, it should extend also to samples from asymptomatic individuals. Sample identification of positively tested individuals would allow determination by follow-up of who was and remained asymptomatic. All viral sequences at centralized sequence repositories then should be annotated for symptomatic or asymptomatic clinical outcomes and other relevant medical parameters, such as age, gender and comorbidities (in accordance with appropriate patient privacy legislation). The next step would be to score for specific genetic determinants of the virus, in particular deletions, that are enriched within the pool of isolates derived from confirmed asymptomatic populations but absent in isolates from symptomatic COVID-19 patients.

The focus should be on those genetic determinants of SARS-CoV-2 isolates that would correlate with asymptomatic outcomes and that would be spread at relatively high frequencies. It is key that these potentially attenuated sequences are also found in individuals who otherwise would be at high-risk of developing severe symptoms from COVID-19, such as 60+ year-old individuals with comorbidities that are considered to be risk factors. These individuals could then be approached to be tested for having undergone seroconversion and, if so, for consistent and prolonged asymptomatic status. Statistics should support whether these individuals would be, at least for some time, protected from reinfection with non-attenuated SARS-CoV-2, with a confidence assessment at least comparable with the current standard for phase III clinical trials concerning a typical designer vaccine. In other words, the pandemic, itself, already may have inadvertently performed a 'natural' clinical trial, which, for regular vaccine development, is by far the most time-consuming step.

On the whole, the current global crisis is of a magnitude such that it is feasible to identify currently existing attenuated SARS-CoV-2 variants and to assess their prevalence. Such an effort would be instrumental not only

to better understand the evolution of SARS-CoV-2 as it spreads among humans but also to predict the dynamics of the current and, possibly, also future pandemics (Ng *et al.*, 2003). Knowledge of SARS-CoV-2 attenuation might also have relevance for developing safer and more effective anti-SARS-CoV-2 vaccines. Live attenuated anti-SARS-CoV-2 vaccines would entail some unknown degree of risk and may cause unpredictable outcomes, for instance, due to recombination events (Zhang *et al.*, 2019), in particular, if the non-attenuated virus would remain widespread. Indeed, designer vaccines have replaced live attenuated vaccines these days because of safety concerns (Vaccine Types available at <https://www.vaccines.gov/basics/types>). We, nevertheless, argue that the determination of naturally circulating attenuated SARS-CoV-2 variants is an urgent matter.

Note added in proof

An interesting study has come out in Medrxiv, supporting the notion that there likely is a wide range in pathogenicity of circulating SARS-CoV-2 variants, as reflected by variable cytopathic effects and production levels of viral progeny in Vero-E6 cells, depending on the SARS-CoV-2 variant these cells were infected with (Yao *et al.*, 2020).

REFERENCES

- Benvenuto, D., Angeletti, S., Giovanetti, M., Bianchi, M., Pascarella, S., Cauda, R., *et al.* (in press) Evolutionary analysis of SARS-CoV-2: how mutation of non-structural protein 6 (NSP6) could affect viral autophagy. *J Infect.* <https://doi.org/10.1016/j.jinf.2020.03.058>.
- Forster, P., Forster, L., Renfrew, C., and Forster, M. (2020) Phylogenetic network analysis of SARS-CoV-2 genomes. *Proc Natl Acad Sci U S A*, **117**(17), 9241–9243. <https://doi.org/10.1073/pnas.2004999117>.
- Grubaugh, N.D., Petrone, M.E., and Holmes, E.C. (2020) We shouldn't worry when a virus mutates during disease outbreaks. *Nat Microbiol* **5**: 529–530.
- Holmes, E.C. (2009) *The Evolution and Emergence of RNA Viruses*, New York, NY: Oxford University Press.
- Ma-Lauer, Y., Carbajo-Lozoya, J., Hein, M.Y., Müller, M.A., Deng, W., Lei, J., *et al.* (2016) p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. *Proc Natl Acad Sci U S A* **113**: E5192–E5201.
- Muth, D., Corman, V.M., Roth, H., Binger, T., Dijkman, R., Gottula, L.T., *et al.* (2018) Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission. *Sci Rep* **8**: 15177.
- Ng, T.W., Turinici, G., and Danchin, A. (2003) A double epidemic model for the SARS propagation. *BMC Infect Dis* **3**: 19.
- Snijder, E.J., Bredenbeek, P.J., Dobbe, J.C., Thiel, V., Ziebuhr, J., Poon, L.L.M., *et al.* (2003) Unique and conserved features of genome and proteome of SARS-

- coronavirus, an early split-off from the coronavirus group 2 lineage. *J Mol Biol* **331**: 991–1004.
- Srinivasan, S., Cui, H., Gao, Z., Liu, M., Lu, S., Mkandawire, W., *et al.* (2020) Structural genomics of SARS-CoV-2 indicates evolutionary conserved functional regions of viral proteins. *Viruses* **12**: 360.
- Su, Y. C. F., Anderson, D. E., Young, B. E., Zhu, F., Linster, M., Kalimuddin, S., *et al.* (in press) Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. doi:<https://doi.org/10.1101/2020.03.11.987222>.
- Yao, H., Lu, X., Chen, Q., Xu, K., Chen, Y., Cheng, L., & Liu, F. (2020) Patient-derived mutations impact pathogenicity of SARS-CoV2. *MedRxiv*, <https://www.medrxiv.org/content/10.1101/2020.04.14.20060160v2>.
- Zhang, W., Zheng, X.S., Agwanda, B., Ommeh, S., Zhao, K., Lichoti, J., *et al.* (2019) Serological evidence of MERS-CoV and HKU8-related CoV co-infection in Kenyan camels. *Emerging Microbes Infect* **8**: 1528–1534.